Adipotide vs Tirzepatide
A targeted fat-destroying peptide that works like a smart missile, cutting off blood supply to fat cells and causing rapid weight loss in primate studies.
The dual-action powerhouse that targets both GIP and GLP-1 receptors, delivering the most dramatic weight loss results ever seen in a medication—averaging over 20% body weight reduction while also crushing blood sugar levels in people with diabetes.
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Quick comparison
Dose range
Adipotide
mg/kg
Tirzepatide
5–10 mg
Frequency
Adipotide
Once daily
Tirzepatide
Once weekly
Administration
Adipotide
Subcutaneous injection
Tirzepatide
Subcutaneous injection
Cycle length
Adipotide
4-6 weeks
Tirzepatide
Ongoing/indefinite
Onset speed
Adipotide
Moderate (1-2 weeks)
Tirzepatide
Moderate (1-2 weeks)
Evidence level
Adipotide
Strong preclinical (extensive animal studies)
Tirzepatide
Strong human trials (Phase 3 or FDA approved)
Benefit ratings
Fat Elimination
Metabolic Improvement
Speed of Results
Weight Loss
Appetite Control
Blood Sugar Control
Compound specifications
Adipotide
Molecular formula
C111H206N36O28S2
Molecular weight
2611.41 g/mol
Half-life
~24 hours
Bioavailability
High (subcutaneous injection)
CAS number
859216-15-2
Tirzepatide
Molecular formula
C225H348N48O68
Molecular weight
4813.45 g/mol
Half-life
Approximately 5 days (120 hours)
Bioavailability
~80% (subcutaneous)
CAS number
2023788-19-2
Dosing compared
Adipotide
Subcutaneous
0.10 mg/kg
Once daily · About 2 weeks before stepping up
Adipotide is research-only and has never been approved for people. These numbers come from a dose-finding study in obese monkeys, where the dose was raised step by step every 2 weeks [2]. The first-in-man Phase 1 study started lower, at 0.03 mg/kg under the skin once daily for 28 days; it enrolled 4 people and was terminated without posting results [5].
0.25 mg/kg
Once daily · About 2 weeks at this step
Middle step in the rhesus macaque dose-finding study — not an approved or established human dose. Renal tubular degeneration with elevated creatinine was dose-dependent in those macaques, and this level sits at the point where that injury was observed. The mechanism makes it expected rather than incidental: adipotide is a homing sequence fused to a pro-apoptotic domain, and the kidney accumulates it. [2]
0.43 mg/kg
Once daily · Up to ~3-4 weeks at this level (studies ran 28 days at the top dose)
This was the best-working ("optimal") dose in obese monkeys, leading to about 10.6% body-weight loss over 28 days. It is from animal research and is not an approved or established human dose. [2]
Tirzepatide
Subcutaneous injection
First 4 weeks
2.5 mg
Once weekly · First 4 weeks
FDA label starting dose; non-therapeutic, used only to improve GI tolerability before escalating [5]. Inject in abdomen, thigh, or upper arm and rotate sites.
Increase by 2.5 mg after at least 4 weeks at each dose
5-10 mg
Once weekly · Increase by 2.5 mg after at least 4 weeks at each dose
Per FDA label, increase to 5 mg after 4 weeks; further increases in 2.5 mg steps no sooner than every 4 weeks as needed [5].
Ongoing maintenance
12.5-15 mg
Once weekly · Ongoing maintenance
15 mg is the maximum FDA-labeled dose [5]. SURMOUNT-1 used up to 15 mg weekly for obesity [1].
Best suited for
Adipotide
Targeted White Fat Reduction
Adipotide specifically seeks out and destroys the blood vessels feeding white adipose tissue. Unlike diet or exercise that shrink fat cells, this peptide actually eliminates fat tissue by cutting off its blood supply - a completely unique mechanism.
Stubborn Fat Deposits
Because it targets the vasculature of fat tissue directly, Adipotide may be particularly effective for stubborn fat deposits that resist traditional methods. The peptide homes in on prohibitin receptors found specifically on blood vessels supplying fat tissue.
Improving Insulin Resistance
Primate studies showed remarkable improvements in insulin sensitivity - treated monkeys used about 50% less insulin after treatment. This makes it interesting for research into obesity-related metabolic dysfunction.
Research Applications
As a pioneering vascular-targeting peptide, Adipotide represents a new class of potential therapeutics. Its unique mechanism of targeting specific tissue vasculature has implications beyond obesity research.
Tirzepatide
People Who Want Maximum Weight Loss Results
If you're serious about losing significant weight, tirzepatide delivers results that were previously only achievable through bariatric surgery. Clinical trials showed average weight loss exceeding 20% of body weight—that's 50+ pounds for someone starting at 250 pounds. No other medication comes close [1].
Those Who Haven't Succeeded with Semaglutide
Thanks to its dual GIP/GLP-1 mechanism, tirzepatide often works better for people who had limited results with GLP-1-only drugs like semaglutide. The added GIP activation provides extra metabolic benefits that can break through plateaus and deliver superior weight loss [2][9].
People with Type 2 Diabetes Needing Aggressive Control
Head-to-head trials proved tirzepatide beats semaglutide for blood sugar control. The average HbA1c reduction of over 2 percentage points means many people can dramatically reduce or eliminate other diabetes medications. It's a genuine game-changer for metabolic health [2].
Individuals Looking to Transform Their Relationship with Food
Tirzepatide doesn't just reduce hunger—it fundamentally changes how food appeals to you. Users describe feeling free from constant food thoughts, finding it easy to stop eating when satisfied, and losing interest in formerly irresistible treats. It's not willpower—it's biochemistry working for you [11].
Side effects
Adipotide
Common
- Elevated Serum Creatinine
- Proteinuria
- Glucosuria
- Reduced Appetite
Uncommon
- Mild Dehydration
- Injection Site Reactions
Serious
- Renal Tubular Dysfunction
Tirzepatide
Common
- Nausea
- Diarrhea
- Decreased Appetite
- Vomiting
Uncommon
- Gallbladder Problems
- Hair Thinning (Telogen Effluvium)
Serious
- Pancreatitis
- Thyroid Tumors (Theoretical Risk)
Safety & evidence
Adipotide
Evidence level
Strong preclinical (extensive animal studies)
FDA status
Research compound
Safety overview
Everything known about adipotide's safety comes from animals. It has been given to mice [1], to mice and rats [4], and to obese monkeys of three different species [2]. The main safety finding is the kidneys. In the monkey study, the doses that worked best also produced changes in the function of the renal proximal tubule — the part of the kidney that reabsorbs what the body needs from filtered blood. Those changes were dose-dependent and they reversed after treatment stopped [2]. The selectivity claim comes from a direct comparison rather than an impression: the same peptide that completely reversed diet-induced obesity in mice on a high-fat diet did not reduce body weight in animals on a low-fat diet [4]. There is no human safety data. One first-in-man Phase 1 study opened in 2012 in men with metastatic prostate cancer and obesity. Four people were enrolled. It was terminated, the registry records the reason as the principal investigator's request rather than a safety finding, and no results have ever been posted [5].
Contraindications
- Kidney disease or impaired renal function
- Pregnancy or breastfeeding
- Active infections or compromised immune system
- History of severe allergic reactions to peptides
- Dehydration or conditions affecting fluid balance
Tirzepatide
Evidence level
Strong human trials (Phase 3 or FDA approved)
FDA status
FDA approved for this use
Safety overview
Tirzepatide has been extensively studied in the SURPASS (diabetes) and SURMOUNT (obesity) trial programs, involving thousands of participants over multiple years. [1][2][3] The FDA approved it after thorough safety review. [5][6] While GI side effects are common (especially during dose increases), they're typically mild to moderate and improve over time. [5][6] Serious adverse events are rare. The SURPASS-CVOT trial is ongoing to evaluate long-term cardiovascular outcomes. [16]
Contraindications
- Personal or family history of medullary thyroid carcinoma (MTC) [6]
- Multiple Endocrine Neoplasia syndrome type 2 (MEN2) [6]
- History of serious allergic reaction to tirzepatide [6] or any GLP-1/GIP medication
Which is right for you?
Choose Adipotide if...
- Targeted fat reduction
- Improving insulin resistance
- Reducing stubborn white adipose tissue
- Research into vascular-targeted therapies
Choose Tirzepatide if...
- Maximum weight loss results
- Long-term obesity management
- Type 2 diabetes control
- Metabolic health improvement